Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maya P. Lipert"'
Autor:
Shuang Chen, Yi Gao, Xiaochun Lou, Rodger F. Henry, DeAnne F. Stolarik, Maya P. Lipert, Ahmad Y. Sheikh, Geoff G. Z. Zhang
Publikováno v:
Molecular Pharmaceutics. 19:2367-2379
Dasabuvir is a non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection. It is an extremely weak diacidic drug (p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a0d0d3baa9ea7f3ed846641af0d38e
https://doi.org/10.1021/acs.molpharmaceut.2c00161
https://doi.org/10.1021/acs.molpharmaceut.2c00161
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
Autor:
W. Peter Wuelfing, Abdellatif El Marrouni, Maya P. Lipert, Pierre Daublain, Filippos Kesisoglou, Antonella Converso, Allen C. Templeton
Publikováno v:
Journal of Medicinal Chemistry. 65:1685-1694
Small molecule developability challenges have been well documented over the last two decades. One of these critical developability parameters is aqueous solubility. In general, more soluble compounds have improved oral absorption. While enabling form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f0104e5a1e99887a5068e337809b9fd
https://doi.org/10.1021/acs.jmedchem.1c01687
https://doi.org/10.1021/acs.jmedchem.1c01687
Publikováno v:
AAPS PharmSciTech. 21(2)
The application and impact of human dose projection (HDP) has been well recognized in the late drug development phase, with increasing appreciation earlier during discovery and early development. This commentary describes the perspective of pharmaceu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497f2fbf9cdbce47710192b123ec8dbb
https://pubmed.ncbi.nlm.nih.gov/31897807
https://pubmed.ncbi.nlm.nih.gov/31897807
Publikováno v:
Journal of pharmaceutical sciences. 106(1)
Poor aqueous solubility of a majority of new small molecule chemical entities is a significant challenge in drug discovery since considerably high exposures are often required to enable pharmacokinetic, pharmacology, and toxicology studies. Pharmaceu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183091cae5dcd38b60014df366bdd804
https://pubmed.ncbi.nlm.nih.gov/27665129
https://pubmed.ncbi.nlm.nih.gov/27665129
Autor:
Maya P. Lipert, Naír Rodríguez-Hornedo
Publikováno v:
Molecular pharmaceutics. 12(10)
In this manuscript we bring together concepts that are relevant to the solubilization and thermodynamic stability of cocrystals in the presence of drug solubilizing agents. Simple equations are derived that allow calculation of cocrystal solubilizati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2166c4491d2f3e27f7338546444cd3cd
https://pubmed.ncbi.nlm.nih.gov/26207517
https://pubmed.ncbi.nlm.nih.gov/26207517
Publikováno v:
Journal of pharmaceutical sciences. 104(12)
This work examines cocrystal solubility in biorelevant media, (FeSSIF, fed state simulated intestinal fluid), and develops a theoretical framework that allows for the simple and quantitative prediction of cocrystal solubilization from drug solubiliza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e08cbe7f960d4944858912422e2a4b
https://pubmed.ncbi.nlm.nih.gov/26390213
https://pubmed.ncbi.nlm.nih.gov/26390213
Autor:
Naír Rodríguez-Hornedo, Maya P. Lipert, Amit Delori, William Jones, Lilly Roy, Ranjit Thakuria
Publikováno v:
International journal of pharmaceutics. 453(1)
In recent years cocrystal formation has emerged as a viable strategy towards improving the solubility and bioavailability of poorly soluble drugs. In this review the success of numerous pharmaceutical cocrystals for the improvement of the solubility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::286849615c21670faad3c712eae02fd2
https://pubmed.ncbi.nlm.nih.gov/23207015
https://pubmed.ncbi.nlm.nih.gov/23207015